241 related articles for article (PubMed ID: 35216202)
1. Dual Nature of RAGE in Host Reaction and Nurturing the Mother-Infant Bond.
Oshima Y; Harashima A; Munesue S; Kimura K; Leerach N; Goto H; Tanaka M; Niimura A; Hayashi K; Yamamoto H; Higashida H; Yamamoto Y
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216202
[TBL] [Abstract][Full Text] [Related]
2. Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior.
Leerach N; Harashima A; Munesue S; Kimura K; Oshima Y; Goto H; Yamamoto H; Higashida H; Yamamoto Y
Glycoconj J; 2021 Jun; 38(3):303-310. PubMed ID: 33108607
[TBL] [Abstract][Full Text] [Related]
3. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
[TBL] [Abstract][Full Text] [Related]
4. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
5. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
7. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
[TBL] [Abstract][Full Text] [Related]
8. Transport of oxytocin to the brain after peripheral administration by membrane-bound or soluble forms of receptors for advanced glycation end-products.
Munesue SI; Liang M; Harashima A; Zhong J; Furuhara K; Boitsova EB; Cherepanov SM; Gerasimenko M; Yuhi T; Yamamoto Y; Higashida H
J Neuroendocrinol; 2021 Mar; 33(3):e12963. PubMed ID: 33733541
[TBL] [Abstract][Full Text] [Related]
9. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
10. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
[TBL] [Abstract][Full Text] [Related]
11. Regulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesis.
Liu XY; Li HL; Su JB; Ding FH; Zhao JJ; Chai F; Li YX; Cui SC; Sun FY; Wu ZY; Xu P; Chen XH
J Neurochem; 2015 Apr; 133(2):187-98. PubMed ID: 25689357
[TBL] [Abstract][Full Text] [Related]
12. The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.
Guo WA; Knight PR; Raghavendran K
Intensive Care Med; 2012 Oct; 38(10):1588-98. PubMed ID: 22777515
[TBL] [Abstract][Full Text] [Related]
13. AGEs, RAGEs and s-RAGE; friend or foe for cancer.
Ahmad S; Khan H; Siddiqui Z; Khan MY; Rehman S; Shahab U; Godovikova T; Silnikov V; Moinuddin
Semin Cancer Biol; 2018 Apr; 49():44-55. PubMed ID: 28712719
[TBL] [Abstract][Full Text] [Related]
14. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
Leung SS; Forbes JM; Borg DJ
Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
[TBL] [Abstract][Full Text] [Related]
15. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
Raucci A; Cugusi S; Antonelli A; Barabino SM; Monti L; Bierhaus A; Reiss K; Saftig P; Bianchi ME
FASEB J; 2008 Oct; 22(10):3716-27. PubMed ID: 18603587
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors.
Singh H; Agrawal DK
Drug Dev Res; 2022 Sep; 83(6):1257-1269. PubMed ID: 35781678
[TBL] [Abstract][Full Text] [Related]
17. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
Lue LF; Yan SD; Stern DM; Walker DG
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
[TBL] [Abstract][Full Text] [Related]
18. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
19. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging.
Teissier T; Boulanger É
Biogerontology; 2019 Jun; 20(3):279-301. PubMed ID: 30968282
[TBL] [Abstract][Full Text] [Related]
20. Activation of the receptor for advanced glycation end products and consequences on health.
Wautier MP; Guillausseau PJ; Wautier JL
Diabetes Metab Syndr; 2017; 11(4):305-309. PubMed ID: 27612394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
